Heterogeneity of KRAS Mutation Status in Rectal Cancer

INTRODUCTION: Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Jo, Peter, König, Alexander, Schirmer, Markus, Kitz, Julia, Conradi, Lena-Christin, Azizian, Azadeh, Bernhardt, Markus, Wolff, Hendrik A., Grade, Marian, Ghadimi, Michael, Ströbel, Philipp, Schildhaus, Hans-Ulrich, Gaedcke, Jochen
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4827807/
https://ncbi.nlm.nih.gov/pubmed/27064574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0153278
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars